Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655311 · ClinicalTrials.gov registry record · Phase 1
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06655311 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 56 participants.
The verdict
NCT06655311, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to different doses of enlicitide chloride over time in the body of healthy participants and participants taking statins, a group of medicines used to reduce the levels of high cholesterol in the bloodstream. The researchers want to learn about the safety of enlicitide chloride when administered at high doses.
Interventions
- OTHER Placebo
- BIOLOGICAL Enlicitide Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2024-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655311
The ClinicalTrials.gov registry entry for NCT06655311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06655311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06655311 about?
NCT06655311 is a clinical study titled "A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)". The goal of this study is to learn what happens to different doses of enlicitide chloride over time in the body of healthy participants and participants taking statins, a group of medicines used to reduce the levels of high cholesterol in the bloodstream. The researchers want to learn about the safe...
What is the current status of trial NCT06655311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-09-30. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT06655311?
The interventions under investigation include: Placebo (OTHER), Enlicitide Chloride (BIOLOGICAL).
Who is sponsoring clinical trial NCT06655311?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.